(redirected from Enterobacteriaceae infections)
Also found in: Dictionary, Medical, Encyclopedia.
Related to Enterobacteriaceae infections: Enterobacter gergoviae
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for Enterobacteriaceae

References in periodicals archive ?
The objective of this study is to evaluate clinical outcomes among levofloxacin, cefepime, and carbapenem used for ESBL-producing Enterobacteriaceae infections. Additional objectives include identifying risk factors that can help tailor antibiotic therapy.
A new study shows a 700% increase in MDR antibiotic-resistant Enterobacteriaceae infections in children admitted to hospitals around the United States.
Haidar et al., "Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections," Clinical Infectious Diseases, vol.
It is suggested that isepamicin represents a therapeutic option against the drug-resistance Enterobacteriaceae infections.{Table 5}
Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum p lactamase producing, Enterobacteriaceae infections: a systematic review.
An estimated 140,000 healthcare-associated Enterobacteriaceae infections occur annually in the U.S., 9,000 of which are caused by CRE.
The annual proportion of Enterobacteriaceae infections caused by K.
Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam, zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections).
In the data presented, a DDS-04 series compound cured infection in a translationally-relevant animal model of urinary tract infection, one of the major sites for Enterobacteriaceae infection. Therapeutic concentrations of the DDS-04 compound were also observed in other major sites in the animal model where life-threatening Enterobacteriaceae infections occur, including the lungs and the bloodstream.
Colistin is a last-resort drug for treating carbapenem-resistant Enterobacteriaceae infections (4).